Key Record Dates
| ClinicalTrials.gov Identifier: | NCT03924856 |
|---|---|
| Brief Title: | Perioperative Pembrolizumab (MK-3475) Plus Neoadjuvant Chemotherapy Versus Perioperative Placebo Plus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle-invasive Bladder Cancer (MIBC) (MK-3475-866/KEYNOTE-866) (KEYNOTE-866) |
| First Submitted : | April 22, 2019 |
| First Submitted that Met QC Criteria : | April 22, 2019 |
| First Posted : | April 23, 2019 |
| Last Update Submitted that Met QC Criteria : | July 30, 2021 |
| Last Update Posted : | August 2, 2021 (Estimate) |